MKGAY News and Press, Merck KGaA ADR From 09/16/20

The following slide deck was published by Merck KGaA ADR in conjunction with this Read more ...

As previously reported , Merck ( OTCPK:MKGAY ) reaffirms slight to moderate organic growth of net sales between € 16.9B -€17.7B and EBITDA pre in a range of € 4.45B - €4.85B for FY2020. More news on: Merck KGaA ADR, MERCK Kommanditgesellschaft auf ...

Immutep Limited (NASDAQ: IMMP ) jumps  36%  premarket on average volume in reaction to preliminary results from a Frankfurt, Germany-based Phase 1 clinical trial evaluating the combination of lead candidate eftilagimod alpha and Pfizer (NYSE: PFE ) and Merck KGaA's ( OTCPK:MKGAY ...

Thinly traded nano cap Vaccinex ( VCNX +9.8% ) is up more than an 8x surge in volume, albeit on turnover of only 289K shares, on the heels of updated data from a Phase 1b/2 clinical trial, CLASSICAL-Lung , evaluating pepinemab, combined with Pfizer ( PFE +1.5% ) and Merck KGaA's ( OTC...

Based on an assessment from the independent Data Monitoring Committee (DMC) that a positive outcome is unlikely, Pfizer ( PFE +4.1% ) and Merck KGaA's ( OTCPK:MKGAY ) EMD Serono have decided to terminate the Phase 3 JAVELIN study evaluating the combination of Bavencio (avelumab) a...

Deals and Financings Abpro Bio, a Korean company, announced a $1.1 billion agreement to acquire Asian rights (including China) to two bi-specific antibody candidates being developed by Abpro of Boston. Abpro Bio, known previously as Ugint (KOSDAQ:195990), manufactures precision machine tools...

The following slide deck was published by Merck KGaA ADR in conjunction with this Read more ...

Seven of the top 10 best-selling drugs in the world are antibodies, biosimilars are starting to disrupt the pharmaceutical industry, and Big Pharma is investing billions in gene therapy. On top of that, roughly half of the drugs in biopharma pipelines today are biologics (antibodies, cell ther...

Results from a Phase 3 clinical trial, JAVELIN Bladder 100 , evaluating Pfizer (NYSE: PFE ) and alliance partner Merck KGaA's ( OTCPK:MKGAY ) Bavencio (avelumab) for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial cancer (UC) whose disease ...

Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...